Ranger Investment boosts stake in Phibro Animal Health amid institutional churn and cautious sentiment

Ranger Investment Management has built a fresh $9.18 million stake in Phibro Animal Health, joining a wave of institutional repositioning even as analyst sentiment cools, with Citigroup and other research firms trimming targets on a stock now trading below its 200-day moving average.

Ranger Investment Management has taken a new position in Phibro Animal Health, purchasing 292,410 shares in the second quarter valued at approximately $9.18 million, according to a filing with the US Securities and Exchange Commission. The stake represents roughly 0.72% of the company.

The purchase adds to a broader pattern of institutional churn. MarketBeat data show Millennium Management, Allspring Global Investments, Castleark Management and Lazard Asset Management have all recently adjusted their Phibro holdings, with hedge funds and institutions collectively controlling 99.34% of the company’s shares.
Broker sentiment remains subdued. MarketBeat records a consensus Hold rating with an average price target of $42.50, though recent analyst activity has turned more cautious — Citigroup cut its target, and several research firms have downgraded their outlook on the stock.

Phibro, which develops animal health and mineral nutrition products across livestock, companion animal and aquaculture markets, has been trading below its 200-day moving average. Shares opened Monday at $36.32, giving the company a market value of approximately $1.47 billion.
The company also declared a quarterly dividend of $0.12 per share, payable 23 September to shareholders of record on 2 September — an annualised yield of approximately 1.3%.